Madrigal Pharmaceuticals (MDGL) Gains from Investment Securities (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Gains from Investment Securities of $2.4 million for Q1 2026, down 38.72% quarter-over-quarter from $4.0 million in Q2 2025.
Madrigal Pharmaceuticals (MDGL) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 15 years of Gains from Investment Securities data on file, last reported at $2.4 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $2.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 368.08% YoY), and the FY2025 annual result was $4.0 million, up 206.31% from the prior year.
- Gains from Investment Securities eased to $2.4 million in Q1 2026 per MDGL's latest filing, from $4.0 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $4.0 million in Q2 2025 and troughed at -$28000.0 in Q4 2023.
- A 4-year average of $1.6 million and a median of $1.4 million in 2023 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 814.29% in 2024 and fell as far as 26.29% in 2024.
- A 4-year view of Gains from Investment Securities shows it stood at -$28000.0 in 2023, then jumped by 814.29% to $200000.0 in 2024, then soared by 1891.0% to $4.0 million in 2025, then tumbled by 38.72% to $2.4 million in 2026.
- Business Quant data shows MDGL's Gains from Investment Securities at $2.4 million in Q1 2026, $4.0 million in Q2 2025, and $200000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.44 Mn |
| Mar 31, 2026 | 2.44 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Dec 31, 2024 | 200,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Dec 31, 2023 | -28,000.00 |
| Dec 31, 2023 | -28,000.00 |
| Sep 30, 2023 | 1.63 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Sep 30, 2020 | 451,000.00 |
| Sep 30, 2020 | 451,000.00 |
| Mar 31, 2019 | 958,345.00 |
| Mar 31, 2019 | 958,345.00 |
| Dec 31, 2018 | 1.13 Mn |
| Dec 31, 2018 | 1.13 Mn |
| Sep 30, 2018 | 1.23 Mn |
| Sep 30, 2018 | 1.23 Mn |